Scotia Capital’s Arcturus Therapeutics ARCT Stock Holding History

Scotia Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,054	Closed	-$415K	–	827
2021 Q1	$415K	Buy	+10,054	New	+$599K	﹤0.01%	640

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Scotia Capital's ARCT Position: Q2 2021 in Review

Scotia Capital sold out of Arcturus Therapeutics (ARCT) in Q2 2021, closing a stake of 10,054 shares — an estimated $415K sold.

Scotia Capital first reported a position in ARCT in Q1 2021 and held it in 1 quarter. The position peaked at $415K in Q1 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q2 2021.

Scotia Capital reported no remaining Arcturus Therapeutics position as of Q2 2021 after selling out during the quarter.
Scotia Capital sold 10,054 Arcturus Therapeutics shares in Q2 2021, an estimated $415K.
Scotia Capital first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 1 quarter.
Scotia Capital's Arcturus Therapeutics position peaked at $415K in Q1 2021.
139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2021.

Based on Scotia Capital's 13F filing for Q2 2021, filed 12 Aug 2021.